

MELAN ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/ Support	STUDY	O R P E E G N	ARM	ACCR. GOAL	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.	DATE OF FIRST REG.	# of ACT. INSTs	# of CURR IRBs	
						LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS				
SWOG	S1320-Adv, BRAF mut, Inter v Contin	1	Y 1	Lead-in Continuous Dosing	280	194	65	31	18	4	1	09/19/2014	230	102
						194	65	31	18	4	1			
		2	Y 2	Continuous Dosing	280	81	28	16	9	5	1	09/19/2014		
				3 Intermittent Dosing		78	25	14	7	5	1			
						159	53	30	16	10	2			
	S1512-Melan, Adv, Desmoplastic, MK-3475 (pembro)	1	Y 1	MK-3475 (pembrolizumab)	77	5	5	4	2	0	0	02/06/2017	76	33
						5	5	4	2	0	0			
	S1616-MELAN, Adv, Ipilimumab ± Nivolumab	1	Y 1	Ipilimumab	94	1	1	1	1	0	0	10/23/2017		60
				2 Nivolumab + Ipilimumab		4	4	4	3	2	1			
						5	5	5	4	2	1			
Yes	EA6134-Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T	1	E	Total Registrations		24	11	8	2	0	0	11/03/2015	353	147
						24	11	8	2	0	0			
		2	E	Total Registrations		5	2	1	0	0	0	11/03/2015		
						5	2	1	0	0	0			
	EA6141-Melan, Adv, Nivolumab+Ipi ± Sargmostim	1	E	Total Registrations		36	21	0	0	0	0	03/25/2016	310	122
						36	21	0	0	0	0			
No	E3612-MELAN, Adv Ipilimumab±Bevacizumab	1	E	Total Registrations		6	1	1	0	0	0	02/16/2015	115	41
						6	1	1	0	0	0			

23-JAN-2018 6:10
MELAN Open Studies with No Registrations

<u>Study</u>	<u>Registration/Phase</u>	<u>Open Date</u>
S1607 MELAN, Adv, T-VEC, MK-3475	1 Registration	02-Oct-17